Business Context and Reporting Period
Company: ANAVEX LIFE SCIENCES CORP.
Filing Type: Form 8-K (Current Report)
Report Date: May 4, 2011
Event: Unregistered sales of equity securities (Item 3.02).
Key Financial Metrics
This filing reports a specific financing transaction rather than comprehensive financial statements. Key metrics related to the transaction include:
- Capital Raised (Transaction): $1,000,000 total convertible debentures arranged; $500,000 issued on May 4, 2011.
- Additional Equity/Warrant Proceeds: $100,000 from the exercise of options for shares and warrants.
- Debt Instrument Terms: 8% annual interest rate; maturity date of May 4, 2012.
- Conversion Price: $3.00 per share (convertible into units of one share and one warrant).
- Warrant Exercise Price: $4.00 per share; exercisable for two years.
Note: The filing text does not provide clear values for total revenue, net profit, operating cash flow, gross margins, total debt, or liquidity ratios.
Material Changes
The primary material change is the issuance of unregistered securities to a non-U.S. person in an offshore transaction relying on Regulation S and Section 4(2) exemptions. Specifically:
- Issuance of one $500,000 convertible debenture on May 4, 2011.
- Issuance of 33,334 shares and 33,334 warrants upon option exercise.
- Expectation that the remaining $500,000 of the convertible debentures will close within one month.
Outlook, Risks, and Management Commentary
Management Commentary: The company confirmed the arrangement of $1,000,000 in convertible debentures and the partial closing of the transaction. The remaining portion is expected to close shortly.
Risks and Contingencies: The securities are unsecured obligations. The transaction was conducted as an offshore sale to a non-U.S. person, relying on specific registration exemptions.
Unusual Items: None reported beyond the standard terms of the convertible debenture and warrant exercise.
Investor Verification Checklist
- Verify the closing status of the remaining $500,000 convertible debentures expected within the next month.
- Confirm the total number of shares and warrants outstanding post-issuance to assess dilution impact.
- Review the company's cash position to determine if the $600,000 raised ($500k debenture + $100k option exercise) is sufficient for near-term operational needs.
- Check for any subsequent filings regarding the full conversion of the debentures or early retirement.